H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 18.2 HKD 2.13%
Market Cap: 108B HKD
Have any thoughts about
Hansoh Pharmaceutical Group Company Ltd?
Write Note

Net Margin
Hansoh Pharmaceutical Group Company Ltd

39%
Current
30%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
39%
=
Net Income
4.7B
/
Revenue
12.1B

Net Margin Across Competitors

Country CN
Market Cap 108B HKD
Net Margin
39%
Country JP
Market Cap 776 550.9T JPY
Net Margin
-79%
Country US
Market Cap 755.8B USD
Net Margin
20%
Country UK
Market Cap 440.4B GBP
Net Margin
-4%
Country DK
Market Cap 2.7T DKK
Net Margin
35%
Country US
Market Cap 351.1B USD
Net Margin
17%
Country US
Market Cap 251.8B USD
Net Margin
19%
Country CH
Market Cap 200.1B CHF
Net Margin
20%
Country UK
Market Cap 161.8B GBP
Net Margin
13%
Country CH
Market Cap 171.5B CHF
Net Margin
35%
Country US
Market Cap 151.5B USD
Net Margin
7%
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Market Cap
108B HKD
Industry
Pharmaceuticals

Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.

Intrinsic Value
16.3 HKD
Overvaluation 10%
Intrinsic Value
Price
H

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
39%
=
Net Income
4.7B
/
Revenue
12.1B
What is the Net Margin of Hansoh Pharmaceutical Group Company Ltd?

Based on Hansoh Pharmaceutical Group Company Ltd's most recent financial statements, the company has Net Margin of 39%.